Allison Brashear1. 1. Department of Neurology, Wake Forest University of Medicine, Winston-Salem, NC, USA. abrashear@wfubmc.edu
Abstract
BACKGROUND: The expanding uses of botulinum neurotoxin (BoNT) for a growing number of clinical indications, including cervical and other dystonias, adult and childhood spasticity, and hyperhidrosis, in conjunction with the emergence of new formulations of BoNT, prompt discussion of the differences in formulations, serotypes, and indications for different neurologic diseases. REVIEW SUMMARY: This review will evaluate evidence from preclinical studies, prospective treatment studies, and direct comparative trials to discuss the differences among BoNTs and the clinical implications of using these different drugs. Data from these sources indicate that formulations of BoNT are distinct; even the same serotype formulations of BoNT serotype A have different molecular structures and sizes and therapeutic indices (reflected in different safety and efficacy profiles). CONCLUSION: Taken together, these findings confirm that the different BoNT serotypes, including the different BoNTA formulations, are distinct therapeutic entities.
BACKGROUND: The expanding uses of botulinum neurotoxin (BoNT) for a growing number of clinical indications, including cervical and other dystonias, adult and childhood spasticity, and hyperhidrosis, in conjunction with the emergence of new formulations of BoNT, prompt discussion of the differences in formulations, serotypes, and indications for different neurologic diseases. REVIEW SUMMARY: This review will evaluate evidence from preclinical studies, prospective treatment studies, and direct comparative trials to discuss the differences among BoNTs and the clinical implications of using these different drugs. Data from these sources indicate that formulations of BoNT are distinct; even the same serotype formulations of BoNT serotype A have different molecular structures and sizes and therapeutic indices (reflected in different safety and efficacy profiles). CONCLUSION: Taken together, these findings confirm that the different BoNT serotypes, including the different BoNTA formulations, are distinct therapeutic entities.
Authors: J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch Journal: Nervenarzt Date: 2011-04 Impact factor: 1.214
Authors: James B Machamer; Edwin J Vazquez-Cintron; Sean W O'Brien; Kyle E Kelly; Amber C Altvater; Kathleen T Pagarigan; Parker B Dubee; Celinia A Ondeck; Patrick M McNutt Journal: Mol Med Date: 2022-06-03 Impact factor: 6.376
Authors: Fábio Coelho Guarany; Paulo Dornelles Picon; Nicole Ruas Guarany; Antonio Cardoso dos Santos; Bianca Paula Mentz Chiella; Carolina Rocha Barone; Lúcia Costa Cabral Fendt; Pedro Schestatsky Journal: PLoS One Date: 2013-02-28 Impact factor: 3.240